Could a diabetes pill protect heart attack patients during emergency artery repair?
NCT ID NCT06342141
First seen Apr 22, 2026 · Last updated May 23, 2026 · Updated 7 times
Summary
This study tests whether empagliflozin, a diabetes drug, can reduce the risk of 'no-reflow'—a dangerous complication where blood flow isn't fully restored after angioplasty for a heart attack. About 162 adults with ST-elevation heart attacks will receive either the drug or a placebo before and for 3 days after the procedure. The goal is to see if the drug helps limit heart muscle damage and improve recovery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NO-REFLOW PHENOMENON are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institute of Cardiology
Mexico City, Mexico City, 14080, Mexico
Conditions
Explore the condition pages connected to this study.